Verve Historical Balance Sheet

VERV Stock

USD 6.31 0.14 2.17%

Trend analysis of Verve Therapeutics balance sheet accounts such as Total Assets of 908.9 M, Short Long Term Debt Total of 70.2 M, Other Current Liabilities of 24.4 M or Total Current Liabilities of 23.1 M provides information on Verve Therapeutics' total assets, liabilities, and equity, which is the actual value of Verve Therapeutics to its prevalent stockholders. By breaking down trends over time using Verve Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Verve Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Verve Therapeutics is a good buy for the upcoming year.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verve Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Verve Stock please use our How to Invest in Verve Therapeutics guide.

About Verve Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Verve Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Verve Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Verve Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Verve currently owns. An asset can also be divided into two categories, current and non-current.

Verve Therapeutics Balance Sheet Chart

At this time, Verve Therapeutics' Non Currrent Assets Other are fairly stable compared to the past year. Cash And Short Term Investments is likely to climb to about 753.4 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 23.1 M in 2025.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of Verve Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Verve Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Verve Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Verve Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Verve Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Verve Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verve Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Verve Stock please use our How to Invest in Verve Therapeutics guide.At this time, Verve Therapeutics' Non Currrent Assets Other are fairly stable compared to the past year. Cash And Short Term Investments is likely to climb to about 753.4 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 23.1 M in 2025.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	81.9M	74.9M	86.1M	70.2M
Total Assets	679.2M	752.7M	865.6M	908.9M

Short Long Term Debt Total Total Assets

Verve Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		0.49	0.95	0.94	1.0	0.97	0.99	0.97	0.89	-0.91	-0.98	0.7	0.98	0.98	0.9	0.84	1.0	0.99	0.85	0.94	0.65	0.82	1.0	0.78	1.0	0.97
Short Long Term Debt Total	0.49		0.52	0.49	0.4	0.68	0.39	0.56	0.57	-0.13	-0.52	-0.07	0.49	0.55	0.39	0.2	0.47	0.4	0.51	0.45	0.96	0.2	0.42	0.89	0.4	0.57
Other Current Liab	0.95	0.52		0.87	0.94	0.92	0.93	0.9	0.9	-0.87	-0.96	0.72	0.98	0.91	0.97	0.79	0.96	0.93	0.86	0.86	0.69	0.8	0.95	0.79	0.94	0.9
Total Current Liabilities	0.94	0.49	0.87		0.94	0.9	0.95	0.91	0.78	-0.86	-0.95	0.75	0.9	0.91	0.79	0.9	0.94	0.95	0.87	1.0	0.67	0.86	0.93	0.81	0.94	0.9
Total Stockholder Equity	1.0	0.4	0.94	0.94		0.94	1.0	0.96	0.86	-0.93	-0.97	0.74	0.97	0.97	0.89	0.87	1.0	1.0	0.83	0.95	0.57	0.85	1.0	0.72	1.0	0.95
Other Liab	0.97	0.68	0.92	0.9	0.94		0.93	0.99	0.93	-0.79	-0.96	0.53	0.95	0.98	0.85	0.71	0.96	0.92	0.85	0.89	0.79	0.69	0.95	0.88	0.94	0.99
Net Tangible Assets	0.99	0.39	0.93	0.95	1.0	0.93		0.95	0.84	-0.93	-0.97	0.74	0.96	0.96	0.87	0.88	0.99	1.0	0.82	0.95	0.56	0.86	0.99	0.71	1.0	0.95
Property Plant And Equipment Net	0.97	0.56	0.9	0.91	0.96	0.99	0.95		0.94	-0.85	-0.96	0.58	0.96	1.0	0.85	0.72	0.96	0.93	0.86	0.89	0.71	0.68	0.97	0.81	0.96	1.0
Current Deferred Revenue	0.89	0.57	0.9	0.78	0.86	0.93	0.84	0.94		-0.81	-0.91	0.56	0.95	0.93	0.92	0.54	0.88	0.82	0.9	0.74	0.73	0.52	0.9	0.8	0.86	0.95
Net Debt	-0.91	-0.13	-0.87	-0.86	-0.93	-0.79	-0.93	-0.85	-0.81		0.91	-0.89	-0.92	-0.86	-0.89	-0.83	-0.91	-0.92	-0.82	-0.85	-0.36	-0.8	-0.94	-0.53	-0.93	-0.85
Retained Earnings	-0.98	-0.52	-0.96	-0.95	-0.97	-0.96	-0.97	-0.96	-0.91	0.91		-0.72	-0.98	-0.97	-0.91	-0.82	-0.98	-0.96	-0.89	-0.94	-0.69	-0.8	-0.98	-0.82	-0.97	-0.96
Accounts Payable	0.7	-0.07	0.72	0.75	0.74	0.53	0.74	0.58	0.56	-0.89	-0.72		0.72	0.6	0.77	0.84	0.72	0.75	0.74	0.75	0.19	0.82	0.75	0.37	0.74	0.58
Cash	0.98	0.49	0.98	0.9	0.97	0.95	0.96	0.96	0.95	-0.92	-0.98	0.72		0.97	0.96	0.77	0.98	0.95	0.9	0.88	0.66	0.75	0.99	0.78	0.97	0.97
Non Current Assets Total	0.98	0.55	0.91	0.91	0.97	0.98	0.96	1.0	0.93	-0.86	-0.97	0.6	0.97		0.86	0.74	0.97	0.95	0.86	0.9	0.7	0.7	0.97	0.81	0.97	1.0
Non Currrent Assets Other	0.9	0.39	0.97	0.79	0.89	0.85	0.87	0.85	0.92	-0.89	-0.91	0.77	0.96	0.86		0.7	0.9	0.86	0.88	0.77	0.59	0.71	0.92	0.69	0.89	0.86
Other Assets	0.84	0.2	0.79	0.9	0.87	0.71	0.88	0.72	0.54	-0.83	-0.82	0.84	0.77	0.74	0.7		0.86	0.91	0.66	0.93	0.37	0.99	0.84	0.55	0.87	0.71
Cash And Short Term Investments	1.0	0.47	0.96	0.94	1.0	0.96	0.99	0.96	0.88	-0.91	-0.98	0.72	0.98	0.97	0.9	0.86		0.99	0.84	0.94	0.63	0.84	0.99	0.77	1.0	0.96
Common Stock Total Equity	0.99	0.4	0.93	0.95	1.0	0.92	1.0	0.93	0.82	-0.92	-0.96	0.75	0.95	0.95	0.86	0.91	0.99		0.8	0.96	0.56	0.89	0.98	0.71	1.0	0.93
Common Stock Shares Outstanding	0.85	0.51	0.86	0.87	0.83	0.85	0.82	0.86	0.9	-0.82	-0.89	0.74	0.9	0.86	0.88	0.66	0.84	0.8		0.83	0.73	0.62	0.86	0.82	0.83	0.87
Short Term Investments	0.94	0.45	0.86	1.0	0.95	0.89	0.95	0.89	0.74	-0.85	-0.94	0.75	0.88	0.9	0.77	0.93	0.94	0.96	0.83		0.62	0.9	0.93	0.77	0.95	0.88
Non Current Liabilities Total	0.65	0.96	0.69	0.67	0.57	0.79	0.56	0.71	0.73	-0.36	-0.69	0.19	0.66	0.7	0.59	0.37	0.63	0.56	0.73	0.62		0.36	0.59	0.98	0.57	0.71
Other Current Assets	0.82	0.2	0.8	0.86	0.85	0.69	0.86	0.68	0.52	-0.8	-0.8	0.82	0.75	0.7	0.71	0.99	0.84	0.89	0.62	0.9	0.36		0.82	0.53	0.85	0.67
Other Stockholder Equity	1.0	0.42	0.95	0.93	1.0	0.95	0.99	0.97	0.9	-0.94	-0.98	0.75	0.99	0.97	0.92	0.84	0.99	0.98	0.86	0.93	0.59	0.82		0.73	1.0	0.97
Total Liab	0.78	0.89	0.79	0.81	0.72	0.88	0.71	0.81	0.8	-0.53	-0.82	0.37	0.78	0.81	0.69	0.55	0.77	0.71	0.82	0.77	0.98	0.53	0.73		0.72	0.81
Net Invested Capital	1.0	0.4	0.94	0.94	1.0	0.94	1.0	0.96	0.86	-0.93	-0.97	0.74	0.97	0.97	0.89	0.87	1.0	1.0	0.83	0.95	0.57	0.85	1.0	0.72		0.95
Property Plant And Equipment Gross	0.97	0.57	0.9	0.9	0.95	0.99	0.95	1.0	0.95	-0.85	-0.96	0.58	0.97	1.0	0.86	0.71	0.96	0.93	0.87	0.88	0.71	0.67	0.97	0.81	0.95

Click cells to compare fundamentals

Verve Therapeutics Account Relationship Matchups

Verve Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	78.4M	384.1M	679.2M	752.7M	865.6M	908.9M
Short Long Term Debt Total	125.2M	2.0M	81.9M	74.9M	86.1M	70.2M
Other Current Liab	7.3M	11.0M	8.9M	20.2M	23.2M	24.4M
Total Current Liabilities	7.3M	22.0M	35.1M	37.0M	42.6M	23.1M
Total Stockholder Equity	(63.9M)	357.4M	550.9M	599.5M	689.4M	723.9M
Property Plant And Equipment Net	4.0M	9.1M	110.7M	107.8M	124.0M	130.2M
Current Deferred Revenue	90K	(13.0M)	20.0M	48.6M	55.8M	58.6M
Net Debt	116.2M	(62.4M)	(33.5M)	(131.3M)	(118.1M)	(112.2M)
Retained Earnings	(66.5M)	(186.9M)	(344.2M)	(544.3M)	(489.9M)	(465.4M)
Accounts Payable	36K	7.1M	2.4M	6.6M	7.6M	4.1M
Cash	9.0M	64.3M	115.4M	206.2M	237.1M	249.0M
Non Current Assets Total	4.4M	17.0M	116.1M	114.7M	131.9M	138.5M
Non Currrent Assets Other	463K	2.7M	585K	6.9M	8.0M	8.4M
Cash And Short Term Investments	72.1M	360.4M	554.8M	624.0M	717.5M	753.4M
Short Term Investments	63.1M	296.1M	439.4M	417.8M	480.4M	271.1M
Liabilities And Stockholders Equity	78.4M	384.1M	679.2M	752.7M	865.6M	908.9M
Non Current Liabilities Total	135.0M	4.7M	93.2M	116.2M	133.6M	85.1M
Other Current Assets	1.9M	13.4M	7.3M	8.1M	9.3M	6.8M
Other Stockholder Equity	(122.5M)	544.4M	895.8M	1.1B	1.3B	1.4B
Total Liab	142.3M	26.8M	128.3M	153.2M	176.2M	108.2M
Net Invested Capital	(63.9M)	357.4M	550.9M	599.5M	689.4M	723.9M
Property Plant And Equipment Gross	4.0M	7.2M	115.6M	118.2M	135.9M	142.7M
Total Current Assets	74.0M	367.1M	563.2M	637.9M	733.6M	770.3M
Accumulated Other Comprehensive Income	8K	(228K)	(694K)	272K	244.8K	257.0K
Capital Stock	3K	49K	62K	82K	94.3K	99.0K
Non Current Liabilities Other	9.7M	4.7M	73.2M	2.9M	3.3M	3.2M
Net Working Capital	66.7M	345.1M	528.1M	600.9M	691.1M	725.6M
Short Term Debt	90K	3.9M	23.8M	10.2M	11.7M	8.4M
Common Stock	3K	49K	62K	82K	94.3K	99.0K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Verve Stock Analysis

When running Verve Therapeutics' price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Verve Historical Balance Sheet

About Verve Balance Sheet Analysis

Verve Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Verve Therapeutics balance sheet Correlations

Verve Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Verve Therapeutics balance sheet Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Verve Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Other Stockholder Equity	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Short Term Investments	+ 1.0	Total Current Liabilities
Net Tangible Assets	+ 1.0	Total Stockholder Equity

Other Stockholder Equity	- 0.98	Retained Earnings
Cash And Short Term Investments	- 0.98	Retained Earnings
Cash	- 0.98	Retained Earnings
Retained Earnings	- 0.98	Total Assets
Net Invested Capital	- 0.97	Retained Earnings
Non Current Assets Total	- 0.97	Retained Earnings